Patents Assigned to DepoMed, Inc.
-
Patent number: 9980903Abstract: Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a biocompatible, hydrophilic, erodible polymer with an active agent incorporated therein, wherein the polymer is one that both swells in the presence of water and gradually erodes over a time period of hours, with swelling and erosion commencing upon contact with gastric fluid, and drug release rate primarily controlled by erosion rate.Type: GrantFiled: June 3, 2011Date of Patent: May 29, 2018Assignee: Depomed, Inc.Inventors: Bret Berner, Jenny Louie-Helm, John W. Shell, Barbara Shell
-
Patent number: 9937142Abstract: The present disclosure is directed to methods and compositions for ameliorating, preventing and treating central nervous system (CNS) disorders. The invention aims to treat subjects suffering from, susceptible to, or diagnosed with CNS disorders, and in particular, to treating patients suffering from those disorders which are associated with neurotransmitter system dysfunction.Type: GrantFiled: February 1, 2017Date of Patent: April 10, 2018Assignee: Depomed, Inc.Inventor: Sui Yuen Eddie Hou
-
Patent number: 9814705Abstract: An intranasal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.Type: GrantFiled: June 23, 2015Date of Patent: November 14, 2017Assignee: Depomed, Inc.Inventors: Peter James Watts, Jonathan David Castile, William Columbus Ian Lafferty, Alan Smith
-
Patent number: 9801816Abstract: Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.Type: GrantFiled: March 7, 2016Date of Patent: October 31, 2017Assignee: Depomed, Inc.Inventors: Bret Berner, Cuiping Chen
-
Patent number: 9597338Abstract: Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.Type: GrantFiled: December 29, 2014Date of Patent: March 21, 2017Assignee: Depomed, Inc.Inventors: Bret Berner, Jenny Louie-Helm, John N. Shell
-
Patent number: 9572780Abstract: Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing full access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any penetration of the immediate-release drug into the prolonged-release portion.Type: GrantFiled: March 9, 2015Date of Patent: February 21, 2017Assignee: DEPOMED, INC.Inventors: Jong Lim, John N. Shell, Jenny Louie-Helm
-
Patent number: 9566258Abstract: The present disclosure is directed to methods and compositions for ameliorating, preventing and treating central nervous system (CNS) disorders. The invention aims to treat subjects suffering from, susceptible to, or diagnosed with CNS disorders, and in particular, to treating patients suffering from those disorders which are associated with neurotransmitter system dysfunction.Type: GrantFiled: September 8, 2015Date of Patent: February 14, 2017Assignee: Depomed, Inc.Inventor: Sui Yuen Eddie Hou
-
Patent number: 9561200Abstract: A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.Type: GrantFiled: December 20, 2013Date of Patent: February 7, 2017Assignee: Depomed, Inc.Inventors: Mark M. Kowalski, James L. Young, Keith A. Moore
-
Patent number: 9301934Abstract: Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.Type: GrantFiled: February 26, 2015Date of Patent: April 5, 2016Assignee: Depomed, Inc.Inventors: Bret Berner, Cuiping Chen
-
Patent number: 9161911Abstract: The present disclosure is directed to methods and compositions for ameliorating, preventing and treating central nervous system (CNS) disorders. The invention aims to treat subjects suffering from, susceptible to, or diagnosed with CNS disorders, and in particular, to treating patients suffering from those disorders which are associated with neurotransmitter system dysfunction.Type: GrantFiled: August 14, 2009Date of Patent: October 20, 2015Assignee: DEPOMED, INC.Inventor: Sui Yuen Eddie Hou
-
Patent number: 9078814Abstract: An intrasnal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.Type: GrantFiled: July 3, 2012Date of Patent: July 14, 2015Assignee: DEPOMED, INC.Inventors: Peter James Watts, Jonathan David Castile, William Columbus Ian Lafferty, Alan Smith
-
Patent number: 8999388Abstract: Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing full access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any penetration of the immediate-release drug into the prolonged-release portion.Type: GrantFiled: March 6, 2014Date of Patent: April 7, 2015Assignee: Depomed, Inc.Inventors: Jong Lim, John N. Shell, Jenny Louie-Helm
-
Patent number: 9000046Abstract: Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.Type: GrantFiled: September 28, 2011Date of Patent: April 7, 2015Assignee: Depomed, Inc.Inventors: Bret Berner, Cuiping Chen
-
Patent number: 8945619Abstract: Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.Type: GrantFiled: November 28, 2012Date of Patent: February 3, 2015Assignee: Depomed, Inc.Inventors: Bret Berner, Jenny Louie-Helm, Gloria Gusler, John N. Shell
-
Patent number: 8889176Abstract: A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.Type: GrantFiled: July 3, 2012Date of Patent: November 18, 2014Assignee: Depomed, Inc.Inventors: Peter James Watts, Jonathan David Castile, William Columbus Lafferty, Alan Smith
-
Patent number: 8802157Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.Type: GrantFiled: July 16, 2013Date of Patent: August 12, 2014Assignee: Depomed, Inc.Inventors: Bret Berner, Sui Yuen Eddie Hou
-
Publication number: 20140186515Abstract: Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing full access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any penetration of the immediate-release drug into the prolonged-release portion.Type: ApplicationFiled: March 6, 2014Publication date: July 3, 2014Applicant: DEPOMED, INC.Inventors: Jong Lim, John N. Shell, Jenny Louie-Helm
-
Publication number: 20140186440Abstract: Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.Type: ApplicationFiled: March 4, 2014Publication date: July 3, 2014Applicant: Depomed, Inc.Inventors: Chien-Hsuan Han, Sui Yuen Eddie Hou, Monica L. Reid
-
Publication number: 20140135395Abstract: Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin treatment. In addition to the foregoing, the gastric retentive gabapentin dosages forms also exhibit decreased blood plasma concentrations and increased bioavailability throughout the dosing regimen.Type: ApplicationFiled: November 22, 2013Publication date: May 15, 2014Applicant: Depomed, Inc.Inventors: Bret Berner, Sui Yuen Eddie Hou, Theophilus J. Gana, Marilou S. Cramer
-
Publication number: 20140107210Abstract: A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.Type: ApplicationFiled: December 20, 2013Publication date: April 17, 2014Applicant: Depomed, Inc.Inventors: Mark M. Kowalski, James L. Young, Keith A. Moore